الإحصائيات الأساسية
| LEI | 5299002IR2GXUBEPKS66 |
| CIK | 1117480 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Chimerix, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| May 1, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35867 Chimerix, Inc. (Exact name of registrant as specified in it |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CHIMERIX, INC. ARTICLE I EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHIMERIX, INC. ARTICLE I The name of the corporation is Chimerix , Inc. (the “Corporation”). ARTICLE II The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is the Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801 and County of New Castle |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2025 Chimerix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 POS AM As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
BY-LAWS CHIMERIX, INC. dated as of April 21, 2025 EX-3.2 Exhibit 3.2 BY-LAWS of CHIMERIX, INC. dated as of April 21, 2025 TABLE OF CONTENTS ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE 1 SECTION 2. OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS SECTION 1. ANNUAL MEETINGS 1 SECTION 2. SPECIAL MEETINGS 1 SECTION 3. VOTING 1 SECTION 4. QUORUM 2 SECTION 5. NOTICE OF MEETINGS 2 SECTION 6. ACTION WITHOUT MEETING 2 ARTICLE III DIRECTORS SECTION 1 |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Chimerix, Inc. (Name of Subject Company) (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par val |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| April 14, 2025 |
Our Jazz High Performance Culture Renée Galá President and Chief Operating Officer Exhibit (a)(1)(K) Our Jazz High Performance Culture Renée Galá President and Chief Operating Officer Chimerix Team, As we move closer to bringing our organizations together, I want to highlight an important aspect of our culture at Jazz: High Performance. |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par val |
|
| April 11, 2025 |
Employee Communication from April 11, 2025 Exhibit (a)(1)(K) Chimerix Pre-Integration FAQ We are thrilled that, subject to close, you will be joining Jazz Pharmaceuticals on our mission to innovate to transform the lives of patients and their families. |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par val |
|
| April 10, 2025 |
Needham Conference Fireside Chat Transcript from April 9, 2025 EX-99.(a)(1)(K) Exhibit (A)(1)(K) Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Jazz Pharmaceuticals Public Limited Company, an Irish public limited company plc (“Parent”) and Chimerix, Inc., a Delaware corporation (“Chimerix”), including statements regarding Parent’s pr |
|
| April 10, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stoc |
|
| April 9, 2025 |
Employee Communication from April 9, 2025 Exhibit (a)(1)(J) More About Jazz – United by Our Purpose Bruce C. Cozadd Chairperson and Chief Executive Officer Chimerix Team, At Jazz, everything we do is driven by a singular purpose: to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par val |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Chimerix, Inc. (Name of Subject Company) (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) |
|
| April 7, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stoc |
|
| April 4, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stoc |
|
| April 2, 2025 |
Employee and Director FAQ, first used on April 2, 2025. Exhibit 99.1 Employee and Director FAQ 1. What is a tender offer? On March 4, 2025, Chimerix and Jazz announced an agreement for the acquisition of Chimerix for $8.55 per share, payable in cash without interest and subject to reduction for any applicable withholding taxes, representing a total consideration of approximately $935 million. The acquisition is structured as a tender offer. All Chimeri |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Chimerix, Inc. (Name of Subject Company) Chimerix, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) Mic |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par val |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Chimerix, Inc. (Name of Subject Company) (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) |
|
| March 28, 2025 |
Employee Communication from March 28, 2025 Exhibit (a)(1)(I) A Message from Jazz’s Chief People Officer Heidi Manna Executive Vice President and Chief People Officer Dear Chimerix Team, It’s been a few weeks since the announcement of our transaction and outreach through the short welcome video from CEO Bruce Cozadd and the Jazz Global Leadership team. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par val |
|
| March 21, 2025 |
arrant to Purchase Stock, dated December 23, 2024, by and between the Registrant and Si Exhibit 10.24 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET |
|
| March 21, 2025 |
Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(D) Offer To Purchase All Outstanding Shares of Common Stock of CHIMERIX, INC. |
|
| March 21, 2025 |
Offer to Purchase, dated March 21, 2025. Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Chimerix, Inc. |
|
| March 21, 2025 |
Subsidiaries of Chimerix, Inc. Exhibit 21.1 Subsidiaries of Chimerix, Inc. Oncoceutics, Inc., a Delaware corporation |
|
| March 21, 2025 |
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CHIMERIX, INC. (Name of Subject Company) PINETREE ACQUISITION SUB, INC. (Offeror) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share |
|
| March 21, 2025 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of CHIMERIX, INC. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 Chimerix, Inc. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Chimerix, Inc. (Name of Subject Company) (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) Michael T. Andriol |
|
| March 21, 2025 |
Chimerix, Inc. Insider Trading Policy and Window Period Policy. Chimerix, Inc. Insider Trading Policy April 2013 Persons Covered This Insider Trading Policy of Chimerix, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and its subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live in their households but w |
|
| March 21, 2025 |
Exhibit (d)(3) STRICTLY PRIVATE & CONFIDENTIAL March 4, 2025 Michael T. Andriole Chief Executive Officer Chimerix, Inc. 2505 Meridian Parkway, Suite 100 Durham, NC 27713 Dear Mr. Andriole, Reference is made to our discussions regarding the proposed acquisition (the “Proposed Transaction”) of all of the issued and outstanding equity interests of Chimerix, Inc. (the “Company”) by Jazz Pharmaceutical |
|
| March 21, 2025 |
Exhibit (d)(2) MUTUAL CONFIDENTIAL DISCLOSURE AND NON-USE AGREEMENT THIS MUTUAL NON-DISCLOSURE AGREEMENT (“Agreement”) is made effective as of December 19, 2024 (the “Effective Date”), by and between CHIMERIX, INC. |
|
| March 21, 2025 |
Exhibit 10.11 Chimerix, Inc. Amended and Restated Officer Severance Benefit Plan Section 1.Introduction. The Chimerix, Inc. Amended and Restated Officer Severance Benefit Plan (the “Plan”) is hereby established effective November 12, 2024 (the “Effective Date”). The purpose of the Plan is to provide for the payment of severance benefits to eligible officers of Chimerix, Inc. (the “Company” as furt |
|
| March 21, 2025 |
Exhibit 10.23 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Employ |
|
| March 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CHIMERIX, INC. |
|
| March 21, 2025 |
Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(C) Offer To Purchase All Outstanding Shares of Common Stock of CHIMERIX, INC. |
|
| March 21, 2025 |
Summary Advertisement as published in The New York Times on March 21, 2025 Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| March 6, 2025 |
Exhibit 99.1 Jazz’s Proposed Acquisition of Chimerix to Further Diversify Oncology Portfolio Reinforces commitment to bringing medicines to patients with significant unmet needs Significant Anticipated Strategic and Financial Benefits Transaction Terms Strong strategic fit: Will strengthen Jazz’s presence in the rare oncology space ~$935 million total consideration Anticipated near-term launch: Ex |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Chimerix, Inc. (Name of Subject Company) Pinetree Acquisition Sub, Inc. (Offeror) Jazz Pharmaceuticals plc (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Chimerix, Inc. (Name of Subject Company) Pinetree Acquisition Sub, Inc. (Offeror) Jazz Pharmaceuticals plc (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of |
|
| March 5, 2025 |
Exhibit 99.1 Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz’s pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, March 5 |
|
| March 5, 2025 |
Employee FAQ, first used on March 5, 2025. Exhibit 99.3 CMRX Employee FAQ 1. Why is Chimerix entering into a transaction with Jazz Pharmaceuticals? · The transaction will accelerate development of our pipeline, expand our commercial footprint, and eventually enable us to reach more patients globally while also delivering significant and certain cash value to our shareholders. · Jazz shares our commitment to advancing first-in-class medicin |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Chimerix, Inc. (Name of Subject Company) Chimerix, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) Mic |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 5, 2025 |
Corporate LinkedIn and Corporate X Post, each first used on March 5, 2025. Exhibit 99.1 |
|
| March 5, 2025 |
Form of E-Mail Response to Investor Inquiry, first used on March 5, 2025. Exhibit 99.4 Subject: Chimerix and Jazz Pharmaceuticals Transaction Good morning, We are very pleased to announce that Chimerix has entered into a definitive agreement to be acquired by Jazz Pharmaceuticals. This is an exciting transaction that provides Chimerix with the capital and global scale to advance our pipeline, expand our commercial footprint, and reach more patients with our innovative t |
|
| March 5, 2025 |
Exhibit 99.1 I am excited to share that we’ve just issued a press release announcing our intention to acquire Chimerix, a biopharmaceutical company with a current focus in oncology on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. You can read the full press release here. I’d like to talk about what we expect this transaction will |
|
| March 5, 2025 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: Chimerix, Inc., a Delaware corporation; Jazz Pharmaceuticals Public Limited Company, an Irish public limited company; and Pinetree Acquisition Sub, Inc., a Delaware corporation Dated as of March 4, 2025 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser in |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (C |
|
| March 5, 2025 |
Exhibit 99.2 Jazz Pharmaceuticals 182,033 followers 1h . We’re pleased to announce that we have entered into a definitive agreement for Jazz to acquire Chimerix, Inc. to further diversify our #oncology pipeline, reinforcing our commitment to delivering novel #cancer treatments to people who need them. The acquisition is subject to successful completion of the tender offer and customary closing con |
|
| March 5, 2025 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: Chimerix, Inc., a Delaware corporation; Jazz Pharmaceuticals Public Limited Company, an Irish public limited company; and Pinetree Acquisition Sub, Inc., a Delaware corporation Dated as of March 4, 2025 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser in |
|
| March 5, 2025 |
Exhibit 99.2 Good morning everyone, Just minutes ago we issued a press release announcing that Chimerix has agreed to be acquired by Jazz Pharmaceuticals for $8.55 per share in cash, that’’s a 72% premium to yesterday’’s closing price. This transaction is a significant step forward that will further accelerate the development of our pipeline, expand our commercial footprint both domestically and, |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Chimerix, Inc. (Name of Subject Company) Chimerix, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number of Class of Securities) Mic |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Chimerix, Inc. |
|
| December 10, 2024 |
Chimerix Corporate Presentation December 10, 2024 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| December 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Chimerix, Inc. |
|
| November 14, 2024 |
Chimerix, Inc. Amended and Restated Officer and Severance Benefit Plan. Exhibit 10.1 Chimerix, Inc. Amended and Restated Officer Severance Benefit Plan Section 1.Introduction. The Chimerix, Inc. Amended and Restated Officer Severance Benefit Plan (the “Plan”) is hereby established effective November 12, 2024 (the “Effective Date”). The purpose of the Plan is to provide for the payment of severance benefits to eligible officers of Chimerix, Inc. (the “Company” as furth |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 12, 2024 Date of Report (Date of earliest event reported) Chimerix, Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Empl |
|
| November 7, 2024 |
Chimerix Corporate Presentation November 7, 2024 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIME |
|
| November 7, 2024 |
Chimerix, Inc. Non-Employee Director Compensation Policy, as amended, dated June 20, 2024. Chimerix, Inc. Non-Employee Director Compensation Policy Last Modified Effective as of June 20, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Chimerix, Inc. (“Chimerix”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Bo |
|
| November 7, 2024 |
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update – Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a. |
|
| August 13, 2024 |
As filed with the Securities and Exchange Commission on August 13, 2024 As filed with the Securities and Exchange Commission on August 13, 2024 Registration No. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Emplo |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| August 13, 2024 |
Chimerix Corporate Presentation Aug 13, 2024 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| August 13, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Chimerix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0.001 pe |
|
| August 13, 2024 |
Chimerix, Inc. Stock Option Grant Notice (2024 Equity Incentive Plan) Chimerix, Inc. (the “Company”) has granted to you (the “Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Chimerix, Inc. 2024 Equity Incentive Plan (“Plan”). The Option is subject to all of the terms and conditions set forth in this Stock Option Grant Notice (the “G |
|
| August 13, 2024 |
Chimerix, Inc. 2024 Equity Incentive Plan Chimerix, Inc. 2024 Equity Incentive Plan Adopted by the Compensation Committee: April 10, 2024 Approved by the Stockholders: June 20, 2024 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of 12:01 a.m. Eastern Standard Time on the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Pri |
|
| August 13, 2024 |
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a. |
|
| August 13, 2024 |
Exhibit 99.3 Chimerix, Inc. Stock Option Grant Notice (Inducement Grant Outside of the 2024 Equity Incentive Plan) Chimerix, Inc. (the “Company”) has granted to you (the “Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). The Option is granted outside of the Chimerix, Inc. 2024 Equity Incentive Plan (“Plan”), and is subject to all of the terms |
|
| July 3, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2024 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 20, 2024 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 1, 2024 |
Chimerix, Inc. 2505 Meridian Parkway, Suite 100 Durham, NC 27713 (919) 806-1074 Chimerix, Inc. 2505 Meridian Parkway, Suite 100 Durham, NC 27713 (919) 806-1074 May 1, 2024 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Chimerix, Inc. Registration Statement on Form S-3 File No. 333-277505 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as a |
|
| May 1, 2024 |
Directorship Offer Letter to Marc D. Kozin, dated March 20, 2024. CHIMERIX.COM March 20, 2024 Marc Kozin Re: Member of the Board of Directors of Chimerix, Inc. Dear Mr. Kozin: It is my sincere pleasure, on behalf of Chimerix, Inc. (“Chimerix”), to offer you a position as a member of the Board of Directors (the “Board”) of Chimerix. Your appointment to the Board is contingent and effective upon your formal acceptance of this offer, which shall be evidenced by you |
|
| May 1, 2024 |
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update – Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| May 1, 2024 |
cmrx2q24corporatepresent Chimerix Corporate Presentation May 1, 2024 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Employer |
|
| April 26, 2024 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 20, 2024 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 21, 2024 |
Exhibit 99.1 Chimerix Appoints Marc D. Kozin to Board of Directors Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appoin |
|
| February 29, 2024 |
Chimerix Corporate Presentation February 29, 2024 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| February 29, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 CHIMERIX, INC. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of CHIMERIX, INC. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Chimerix, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [● |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 Chimerix, Inc. |
|
| February 29, 2024 |
Chimerix, Inc. Incentive Compensation Recoupment Policy, adopted on November 14, 2023. 288853836 v4 CHIMERIX, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of CHIMERIX, INC., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) pro |
|
| February 29, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 CHIMERIX, INC. AND , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of CHIMERIX, INC. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Chimerix, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and hav |
|
| February 29, 2024 |
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update – ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a. |
|
| February 29, 2024 |
Subsidiaries of Chimerix, Inc. Exhibit 21.1 Subsidiaries of Chimerix, Inc. Oncoceutics, Inc., a Delaware corporation |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Chimerix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Re |
|
| February 29, 2024 |
Directorship Offer Letter to Lisa L. Decker, PhD, dated December 28, 2023. CHIMERIX.COM December 27, 2023 Re: Member of the Board of Directors of Chimerix, Inc. Dear Ms. Decker: It is my sincere pleasure, on behalf of Chimerix, Inc. (“Chimerix”), to offer you a position as a member of the Board of Directors (the “Board”) of Chimerix. Your appointment to the Board is contingent and effective upon your formal acceptance of this offer, which shall be evidenced by you signin |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Emp |
|
| February 29, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.2 CHIMERIX, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table of Contents Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.03 |
|
| February 29, 2024 |
dated February 29, 2024, by and between the Company and Jefferies LLC. Exhibit 10.27 OPEN MARKET SALE AGREEMENT1 February 29, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Chimerix, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, |
|
| February 29, 2024 |
irst Amendment to Loan and Security Agreement, dated November 21, 2 Exhibit 10.22 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Agreement”) is entered into as of November 21, 2023, by and between Silicon V |
|
| February 29, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 CHIMERIX, INC. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of CHIMERIX, INC. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [·], between Chimerix, Inc., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [· |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 14, 2024 |
CMRX / Chimerix, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CHIMERIX, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2024 |
EX-1 2 tm246065d6ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a |
|
| February 12, 2024 |
CMRX / Chimerix, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm245464d4sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chimerix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate |
|
| December 29, 2023 |
Exhibit 99.1 Chimerix Appoints Lisa Decker to Board of Directors Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience DURHAM, N.C., December 29, 2023 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today a |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2023 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 4, 2023 |
Employment Offer Letter to Michelle LaSpaluto, dated November 30, 2023. |
|
| December 4, 2023 |
Exhibit 99.1 Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer Proven Leader Brings More Than 25 Years of Financial Experience DURHAM, N.C., December 4, 2023 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mic |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2023 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Empl |
|
| November 16, 2023 |
2505 Meridian Pkwy, Suite 100 I Durham, NC 27713 Exhibit 99.2 CHIMERIX.COM September 27, 2023 Thomas J. Riga 1608 Lookout Circle Waxhaw, NC 28173 Dear Tom, Chimerix is pleased to extend an offer of employment to you for the position of Chief Operating Officer and Chief Commercial Officer. This position reports to Michael Andriole, Chief Executive Officer. Our offer of employment is contingent on successful completion of our background screening |
|
| November 16, 2023 |
Exhibit 99.1 Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development DURHAM, N.C., November 16, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2023 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 2, 2023 |
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update – Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conference Call at 8:30 a. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Empl |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIME |
|
| November 2, 2023 |
Chimerix Corporate Presentation November 2, 2023 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| September 29, 2023 |
CMRX / Chimerix Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CHIMERIX, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number) September 19, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Employ |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| August 3, 2023 |
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update – Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in First Half 2024 – – Capital Available to Fund Operations is $233 Million as of June 30, 2023 – – Conference Call at 8:30 a. |
|
| August 3, 2023 |
cmrx3q23corporatepresent Chimerix Corporate Presentation August 3, 2023 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2023 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 27, 2023 |
Chimerix, Inc. Non-Employee Director Compensation Policy Last Modified: June 27, 2023 Exhibit 99.4 Chimerix, Inc. Non-Employee Director Compensation Policy Last Modified: June 27, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Chimerix, Inc. (“Chimerix”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Boar |
|
| June 27, 2023 |
Exhibit 99.3 Mike Andriole 2015 Strathmoor Blvd. Louisville, KY 40205 Dear Mike, Chimerix is pleased to confirm your continued employment in the role of President and Chief Executive Officer, reporting to the Board of Directors. This Amended Offer Letter will be effective on August 1, 2023 (the “Transition Date”). The following are the terms of this offer: Base Salary: Your annual base salary will |
|
| June 27, 2023 |
Exhibit 99.1 Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 – Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the live |
|
| June 27, 2023 |
Exhibit 99.2 June 27, 2023 Michael Sherman 1817 Milford Street Carmel, IN 46032 Re: Management Transition Dear Mike: This letter agreement will serve to memorialize our mutual understanding regarding the transition of your employment with Chimerix, Inc. (the “Company”). Effective as of August 1, 2023 (the “Transition Date”), you will retire as Chief Executive Officer of the Company, your employmen |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2023 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| May 4, 2023 |
cmrx2q23corporatepresent Chimerix Corporate Presentation Q2 2023 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Employer |
|
| May 4, 2023 |
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update – European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – – Conference Call at 8:30 a. |
|
| May 2, 2023 |
CMRX / Chimerix Inc / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chimerix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number) April 30, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Chimerix, Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0.001 par value per share, reser |
|
| March 2, 2023 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Chimerix, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable pr |
|
| March 2, 2023 |
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update – Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No Debt – – Conference Call at 8:30 a. |
|
| March 2, 2023 |
Employment Offer Letter to Allen Melemed dated May 7, 2020. [LETTERHEAD OF CHIMERIX INC] May 7, 2020 Allen S. Melemed, M.D., M.B.A. 375 Fox Pond Road Aiken, SC 29801 Dear Allen, Chimerix is pleased to extend an offer of employment to you for the position of Chief Medical Officer. This position reports to Mike Sherman, President and CEO. Our offer of employment is contingent on successful completion of our background screening process including, but not lim |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 Chimerix, Inc. |
|
| March 2, 2023 |
chimerix1q23corporatepre Chimerix Corporate Presentation 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. |
|
| March 2, 2023 |
Subsidiaries of Chimerix, Inc. Exhibit 21.1 Subsidiaries of Chimerix, Inc. Oncoceutics, Inc., a Delaware corporation |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of (Commission File Number) (IRS Employe |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 1 a20230302cmrxs-8evergreens.htm S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of Incorpor |
|
| February 14, 2023 |
SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Chimerix, Inc. (Title of Class |
|
| February 14, 2023 |
EX-99.1 2 pt7213gab.htm JOINT FILING AGREEMENBT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behal |
|
| February 13, 2023 |
CMRX / Chimerix Inc / Opaleye Management Inc. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CHIMERIX, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16934W106 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108, 617-229-5085 (Name, Address and Te |
|
| February 13, 2023 |
CMRX / Chimerix Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 12, 2023 |
Chimerix, Inc 41 st Annual J.P. Morgan Healthcare Conference January 12, 2023 Exhibit 99.1 Chimerix, Inc 41 st Annual J.P. Morgan Healthcare Conference January 12, 2023 2 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - looking statemen |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 Chimerix, Inc. |
|
| December 9, 2022 |
Chimerix Corporate Presentation Exhibit 99.2 Chimerix Corporate Presentation 2 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - looking statements include those relating to, among other thin |
|
| December 9, 2022 |
Exhibit 99.1 Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update – Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis – – Two external analyses presented at SNO concluded |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Chimerix, Inc. |
|
| December 9, 2022 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMended and restated BYLAWS OF Chimerix, Inc. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation?s Board o |
|
| November 10, 2022 |
CMRX / Chimerix Inc / Rubric Capital Management LP - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Chimerix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address and Tele |
|
| November 3, 2022 |
Chimerix Corporate Presentation Exhibit 99.2 Chimerix Corporate Presentation 2 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - looking statements include those relating to, among other thin |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIME |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Chimerix, Inc. |
|
| November 3, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| November 3, 2022 |
Exhibit 99.1 Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update – ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November – – Meeting with U.S. Food and Drug Administration (FDA) Set for Fourth Quarter – – Strong Financial Position with ~$285 Million in Cash at September 30 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., November 3, 2022 – C |
|
| November 3, 2022 |
Exhibit 10.2 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 1 2. AMENDMENT/MODIFICATION NO P00001 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ NO N/A. 5. PROJECT NO (if applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (if other than line item 6) CODE ASPR-BARDA02 ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 |
|
| September 28, 2022 |
Exhibit 2.1 Execution Version FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT THIS FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT, dated as of September 26, 2022 (this ?Amendment?), is being entered into by and between Chimerix, Inc., a Delaware corporation (the ?Seller?), Emergent BioSolutions Inc., a Delaware corporation (?Emergent?) and Emergent Biodefense Operations Lansing LLC, a Delaware limited li |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 Chimerix, Inc. |
|
| September 28, 2022 |
CHIMERIX, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 CHIMERIX, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Sale of TEMBEXA On September 26, 2022 (the ?Closing Date?), Chimerix, Inc. (the ?Company?), completed the previously announced sale of the Company?s exclusive worldwide rights to brincidofovir, including TEMBEXA and related assets (the ?EBS Agreement?) to Emergent BioSolutions, Inc. (?EBS?). Based on the terms of the |
|
| August 31, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 26, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 8, 2022 |
Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update – ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized – – U. |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 July 29, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| July 5, 2022 |
CMRX / Chimerix Inc / Moll Peter Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.J* Chimerix, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 16934W106 (CU SIP Number) June 17, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 28, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 23, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| May 18, 2022 |
Exhibit 2.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ?[***]?) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version ASSET PURCHASE AGREEMENT between: Chimerix, Inc., a Delaware corporation; and Emergent BioSolutions Inc., a Delaware corporation. Dated as of May 15, 2022 TABLE OF CONTENTS 1. Sale and Purchase of |
|
| May 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 15, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 16, 2022 |
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 million plus Royalties ? $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics ? ? Transaction Allows Focus on Development Pipeline ? ? Positions TEMBEXA with Leading Global Biodefense Partner to Maximize Long Term Value ? DURHAM, N.C., May 16, 202 |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| May 16, 2022 |
Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update Receiving up to $337. |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 2, 2022 |
CMRX / Chimerix Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2022 |
DEF 14A 1 chimerixinc-proxystatement.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of t |
|
| April 28, 2022 |
DEFA14A 1 noticecard2022-defa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Sta |
|
| April 18, 2022 |
Chimerix, Inc. Officer Severance Benefit Plan, as amended. Exhibit 10.1 Chimerix, Inc. Officer Severance Benefit Plan Section 1. Introduction. The Chimerix, Inc. Officer Severance Benefit Plan (the ?Plan?) is hereby established effective February 21, 2013 (the ?Effective Date?). The purpose of the Plan is to provide for the payment of severance benefits to eligible officers of Chimerix, Inc. (the ?Company?) in the event that such officers become subject t |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Chimerix, Inc. |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Chimerix, Inc. |
|
| March 1, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Chimerix, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable pr |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Chimerix, Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0.001 par value per share - - - - - - Equ |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 Chimerix, Inc. |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Chimerix, Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0.001 par value per share - - - - - - Equ |
|
| March 1, 2022 |
Subsidiaries of Chimerix, Inc. Exhibit 21.1 Subsidiaries of Chimerix, Inc. Oncoceutics, Inc., a Delaware corporation |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update ? TEMBEXA RFP Response Submitted and Under Review with BARDA ? ? Pre-Clinical CMX521 Data Accepted for Late Breaking Oral Presentation at International Conference on Antiviral Research ? ? ONC201 Program Remains on Track ? ? Conference Call at 8:30 a. |
|
| March 1, 2022 |
EX-FILING FEES 4 ex107-2022sx8.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Chimerix, Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to be Paid Equi |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 S-8 1 a20220301cmrxs-8evergreens.htm S-8 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of Incorpor |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Chimerix, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Shar |
|
| February 14, 2022 |
CMRX / Chimerix Inc / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chimerix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 16934W106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 3, 2022 |
CMRX / Chimerix Inc / Cantex Pharmaceuticals, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chimerix, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 16934W106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 31, 2022 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| February 1, 2022 |
CMRX / Chimerix Inc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CHIMERIX, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16934W106 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Authorized to R |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 29, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 22, 2021 |
Post Society for Neuro - Oncology Management Conference Call November 22, 2021 © 2021 Chimerix, Inc Exhibit 99.1 Post Society for Neuro - Oncology Management Conference Call November 22, 2021 ? 2021 Chimerix, Inc 2 Forward - Looking Statements These slides contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - l |
|
| November 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 4, 2021 |
Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma ? Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIME |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 4, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| November 4, 2021 |
Exhibit 10.2 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 4 2. AMENDMENT/MODIFICATION NO P00067 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ |
|
| November 4, 2021 |
Exhibit 10.1 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO P00066 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ NO N/A. 5. PROJECT NO (if applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (if other than line item 6) CODE ASPR-BARDA02 ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 |
|
| November 4, 2021 |
Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update ? Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma ? ? U. |
|
| August 5, 2021 |
Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update ? Received U. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 5, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| June 25, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 6, 2021 |
Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update ? BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 ? ? DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose ? ? Conference Call at 8:30 a. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, |
|
| May 6, 2021 |
As filed with the Securities and Exchange Commission on May 6, 2021 Registration No. |
|
| May 6, 2021 |
Exhibit 99.1 Oncoceutics, Inc. Index Page Independent Auditor's Report 2 Financial Statements Balance Sheets 3 Statements of Operations 4 Statements of Changes in Stockholders' Equity 5 Statements of Cash Flows 6 Notes to Financial Statements 7 1 Independent Auditor's Report To the Board of Directors Oncoceutics, Inc. We have audited the accompanying financial statements of Oncoceutics, Inc., whic |
|
| May 6, 2021 |
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO P00065 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ NO N/A. 5. PROJECT NO (if applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (if other than line item 6) CODE ASPR-BARDA02 ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 ASPR-BARDA 33 |
|
| May 6, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2021 |
CHIMERIX, INC. UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 CHIMERIX, INC. UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL STATEMENTS On January 7, 2021, Chimerix, Inc., a Delaware corporation (the ?Company?), Ocean Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (?Merger Sub?), Oncoceutics, Inc., a Delaware corporation (?Oncoceutics?), and Fortis Advisors, LLC solely in its capacity as representative of |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction (Commission File Number) (IRS Employer Iden |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 22, 2021 Date of Report (Date of earliest event reported) Chimerix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35867 33-0903395 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 27, 2021 |
Chimerix Appoints Vicki Vakiener to Board of Directors Exhibit 99.1 Chimerix Appoints Vicki Vakiener to Board of Directors DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Vicki Vakiener to its Board of Directors, effective immediately. Ms. Vakiener currently serves as Ch |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 Chimerix, Inc. |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
